Summary of patient data and outcomes
| Patient no. . | Sokal risk group . | Months on imatinib prior to discontinuation . | Clinical response at time of discontinuation . | Clinical response at time of discontinuation according to ELN . | Months without imatinib . | WBC and cytogenetic response before reintroduction . | Months of imatinib therapy after reintroduction . | Clinical response after restarting imatinib (time to response, months) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Low | 9 | MMR | Optimal | 9 | 7.3, no MCyR | 30 | CMR (12) | Maintained CMR on imatinib therapy |
| 2* | Low | 42 | CCyR | Suboptimal | 9 | 48.2, no MCyR | 18 | Failure to achieve MCyR, subsequent lost of CHR | Imatinib increased to 600 mg after 8 o, then changed to dasatinib. The patient achieved CCyR at 12 mo |
| 3 | Low | 21 | CCyR | Suboptimal | 13 | 88.8†, no MCyR | 26 | CCyR (24) | On imatinib; no MMR after 26 mo |
| 4 | Low | 19 | CCyR | Suboptimal | 23 | 60.3, no MCyR | 29 | no MCyR | Failure to achieve any degree of cytogenetic response. Patient lost to follow-up after 29 mo |
| 5 | Low | 14 | MMR | Optimal | 6 | 5.3, no MCyR | 90 | MMR (9) | Patient remains in MMR |
| 6 | High | 7 | MCyR | Suboptimal | 8 | 79.4, no MCyR | 50 | MCyR (4) | Patient failed to regain MCyR; the dose of imatinib was increased to 600 mg after 11 mo and then changed to dasatinib. Subsequently the patient achieved CCyR after 6 mo of dasatinib therapy |
| 7 | Low | 50 | MMR | Optimal | 13 | 6.5, MCyR | 14 | MMR (3) | Patient remains in MMR with a continuing decline in transcript levels |
| Patient no. . | Sokal risk group . | Months on imatinib prior to discontinuation . | Clinical response at time of discontinuation . | Clinical response at time of discontinuation according to ELN . | Months without imatinib . | WBC and cytogenetic response before reintroduction . | Months of imatinib therapy after reintroduction . | Clinical response after restarting imatinib (time to response, months) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Low | 9 | MMR | Optimal | 9 | 7.3, no MCyR | 30 | CMR (12) | Maintained CMR on imatinib therapy |
| 2* | Low | 42 | CCyR | Suboptimal | 9 | 48.2, no MCyR | 18 | Failure to achieve MCyR, subsequent lost of CHR | Imatinib increased to 600 mg after 8 o, then changed to dasatinib. The patient achieved CCyR at 12 mo |
| 3 | Low | 21 | CCyR | Suboptimal | 13 | 88.8†, no MCyR | 26 | CCyR (24) | On imatinib; no MMR after 26 mo |
| 4 | Low | 19 | CCyR | Suboptimal | 23 | 60.3, no MCyR | 29 | no MCyR | Failure to achieve any degree of cytogenetic response. Patient lost to follow-up after 29 mo |
| 5 | Low | 14 | MMR | Optimal | 6 | 5.3, no MCyR | 90 | MMR (9) | Patient remains in MMR |
| 6 | High | 7 | MCyR | Suboptimal | 8 | 79.4, no MCyR | 50 | MCyR (4) | Patient failed to regain MCyR; the dose of imatinib was increased to 600 mg after 11 mo and then changed to dasatinib. Subsequently the patient achieved CCyR after 6 mo of dasatinib therapy |
| 7 | Low | 50 | MMR | Optimal | 13 | 6.5, MCyR | 14 | MMR (3) | Patient remains in MMR with a continuing decline in transcript levels |
MCyR indicates major cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response; and CMR, complete molecular response.
Patient 2 had 2 pregnancies; the data shown in the table correspond to the second pregnancy. In the first pregnancy, imatinib was discontinued for 11 months after 3 months of therapy.
Patient 3 required leukapheresis, which was started when the WBC rose above 100 × 109 cells/L.